1st Quarter - Amendment

THE LIAISON GROUP, LLC for NATIONAL CANNABIS ROUNDTABLE

Firm
Client
Income
$65,500
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 14, 2023 $65,500 Replaced
1st Quarter - Amendment (this page) Apr 17, 2023 $65,500 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Banking BAN

Ensuring cannabis businesses have access to financial services (in former Congresses the SAFE Banking Act)

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Government Issues GOV

Allowing District of Columbia to have autonomy on issues of creating a regulated cannabis marketplace

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Working on appropriations provisions that prevent the Department of Justice from interfering in state legal cannabis programs (both medical and adult use), allowing JAG Bryne funding to be used for expungements, banking language, various language proposals allowing veterans to access cannabis, fairness in federal drug testing, language protecting tribal sovereignty on cannabis decisions, and language promoting further research into cannabis.

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Law Enforcement/Crime/Criminal Justice LAW

Bills to reduce criminal penalties of cannabis possession and distribution, including but not limited to for bills that remove cannabis from the Schedules in the Controlled Substances Act. Also active on provisions that would facilitate expungements of cannabis offenses including the Misdemeanor Expungement Act and the HOPE Act.

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; SENATE

Consumer Issues/Safety/Products CSP

Engaging with Congress on issues surrounding packaging, labeling, and tracing of regulated cannabis products. Educating on difference between cannabis, synthetic substances, and hemp-derived intoxicating products

LobbyistCovered position, as disclosed
RACHAEL GALOOB —
DAVID MANGONE New Charlie Rangel March 2016- December 2016

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.